A new U.S. study found Anoro Elipta to be better than Bevespi Aerosphere or Stiolto Respimat at lowering the risk of disease flares in COPD.

Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors, and leads to increased ...

Researchers estimate the number of people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050. There are certain risk factors for COPD, including obesity and ...

Medication non-adherence among people with chronic obstructive pulmonary disease (COPD) is a result of lack of affordability and lack of knowledge about medications, among other factors, according ...

For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...

The U.S. Food and Drug Administration on Tuesday approved the first generic Symbicort drug used to treat asthma and chronic obstructive pulmonary disease (COPD), which are two common pulmonary health ...

Roflumilast, a drug recently approved in the United States to treat severe chronic obstructive pulmonary disease (COPD), increases the production of a protein that causes inflammation, which possibly ...

Recent medical research reveals promising developments in the treatment of patients suffering from both diabetes and chronic obstructive pulmonary disease. The study, involving nearly 394,000 adults, ...

The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary disease ...

Delve into the field of pulmonary hypertension as GSK places a $950M bet on 35Pharma's candidate HS235 following the footsteps of Winrevair.